BioSpace News Archive

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2020 financial results will be released after market close on Monday, November 9, 2020

Waters Corporation (NYSE:WAT) today introduced the new RADIAN™ ASAP™ System, a novel direct mass detector engineered for non-mass spectrometry (MS) experts to conduct fast and accurate analyses of solids and liquids with minimal sample prep.

DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU ® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy

Study shows significant cognitive improvement in domains related to language and caregivers reported improved language and daily functioning Lead drug candidate continues to be safe and well-tolerated

Decibel Therapeutics , a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with profound, congenital hearing loss c

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 fourth quarter and full year ended September 30, 2020, before the opening of the market on Monday, November 23, 2020. The company plans to hold a conference call and live a

Seagen Inc. (Nasdaq: SGEN) announced today that it will host a virtual R&D day for investors and analysts on Monday, November 16, 2020 beginning at 10:00 a.m. Eastern Time. The program will include a presentation by members of Seagen leadership on the broad clinical development of the Company’s marketed products, ADCETRIS ® (brentuximab vedotin), PADCEV ® (enfortumab vedotin-ejfv) and TUKYSA ® (tucatinib), and its d

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, November 10, 2020, at 8:30 a.m. ET to review its third quarter 2020 financial results and provide an update on the company.

Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference

Citi today announced the firm has been selected by Gavi, the Vaccine Alliance, to be the financial advisor for the COVAX Facility, its global procurement mechanism for COVID-19 vaccines.